Smart glasses and haptic wearables turn visual scenes into sound and touch, helping blind and low‑vision users read, navigate and interpret social cues with greater independence.

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while delivering rapid remissions for hard‑to‑treat patients.

Electronic retinal implants such as the PRIMA system bypass damaged cells to restore partial central vision, bringing high‑tech artificial sight closer to everyday clinical reality.

No gene acts alone: interacting variants and protein partnerships can worsen, mask or even rescue disease risk, demanding multidimensional, context‑aware models of genetic prediction.

A new mRNA-based method reprograms immune cells directly inside solid tumors, boosting anti-cancer activity and paving the way for next-generation therapies.

Chromosome rearrangements flip, duplicate and move genes, reshaping gene control beyond exomes and non‑coding RNAs and ushering in a new era of high‑resolution genomic medicine.

New U.S. dietary guidelines push meat and animal-based products while underplaying plant-based vegetarian options. More balanced public health messaging may be warranted.

Discontinuing obesity medicines means the weight comes back and people lose the cardiovascular and metabolic benefits conferred by the drugs.

Greenland sharks maintain sharp vision for centuries, revealing powerful DNA repair and eye-protection strategies that may inspire future approaches to lifelong human eyesight.

An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle strength, mobility, and survival.